Contemporary Update on Clinical and Experimental Prostate Cancer Biomarkers: A Multi-Omics-Focused Approach to Detection and Risk Stratification.

Simple Summary: Multi-omics has become a crucial tool in cancer biomarker discovery over the last decade, including for prostate cancer. This approach integrates data from various biological layers, enhancing our understanding of complex, heterogeneous cancers. Multi-omics accelerates precision medicine by identifying new biomarkers and therapeutic targets, potentially improving treatment options for advanced prostate cancer patients. This review discusses traditional prostate cancer biomarkers and highlights recent single-omics and multi-omics advances that have improved clinical diagnostic and prognostic capabilities. Prostate cancer remains a significant health challenge, being the most prevalent non-cutaneous cancer in men worldwide. This review discusses the critical advancements in biomarker discovery using single-omics and multi-omics approaches. Multi-omics, integrating genomic, transcriptomic, proteomic, metabolomic, and epigenomic data, offers a comprehensive understanding of the molecular heterogeneity of prostate cancer, leading to the identification of novel biomarkers and therapeutic targets. This holistic approach not only enhances the specificity and sensitivity of prostate cancer detection but also supports the development of personalized treatment strategies. Key studies highlighted include the identification of novel genes, genetic mutations, peptides, metabolites, and potential biomarkers through multi-omics analyses, which have shown promise in improving prostate cancer management. The integration of multi-omics in clinical practice can potentially revolutionize prostate cancer prognosis and treatment, paving the way for precision medicine. This review underscores the importance of continued research and the application of multi-omics to overcome current challenges in prostate cancer diagnosis and therapy. [ABSTRACT FROM AUTHOR]